Literature DB >> 10801172

Radiotherapy for Graves' orbitopathy: randomised placebo-controlled study.

M P Mourits1, M L van Kempen-Harteveld, M B García, H P Koppeschaar, L Tick, C B Terwee.   

Abstract

BACKGROUND: The best treatment (steroids, irradiation, or both) for moderately severe Graves' orbitopathy, a self-limiting disease is not known. We tested the efficacy of external beam irradiation compared with sham-irradiation.
METHODS: In a double-blind randomised clinical trial, 30 patients with moderately severe Graves' orbitopathy had radiotherapy (20 Gy in ten fractions), and 30 were assigned sham-irradiation (ten fractions of 0 Gy). Treatment outcome was measured qualitatively by changes in major and minor criteria and quantitatively in several ophthalmic and other variables, such as eyelid aperture, proptosis, eye movements, subjective eye score, and clinical-activity score at 24 weeks.
FINDINGS: The qualitative treatment outcome was successful in 18 of 30 (60%) irradiated patients versus nine of 29 (31%) sham-irradiated patients at week 24 (relative risk [RR]=1.9 [95% CI 1.0-3.6], p=0.04). This difference was caused by improvements in diplopia grade, but not by reduction of proptosis, nor of eyelid swelling. Quantitatively, elevation improved significantly in the radiotherapy group, whereas all other variables remained unchanged. The field of binocular single vision was enlarged in 11 of 17 patients after irradiation compared with two of 15 after sham-irradiation. Nevertheless, only 25% of the irradiated patients were spared from additional strabismus surgery.
INTERPRETATION: In these patients with moderately severe Graves' orbitopathy, radiotherapy should be used only to treat motility impairment.

Entities:  

Mesh:

Year:  2000        PMID: 10801172     DOI: 10.1016/S0140-6736(00)02165-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  49 in total

Review 1.  Does radiotherapy have a role in the management of thyroid orbitopathy? View 1.

Authors:  Kimberley P Cockerham; John S Kennerdell
Journal:  Br J Ophthalmol       Date:  2002-01       Impact factor: 4.638

Review 2.  Novel aspects of immunosuppressive and radiotherapy management of Graves' ophthalmopathy.

Authors:  C Marcocci; M Marinò; R Rocchi; F Menconi; E Morabito; A Pinchera
Journal:  J Endocrinol Invest       Date:  2004-03       Impact factor: 4.256

Review 3.  Recent developments in thyroid eye disease.

Authors:  Tom Cawood; Paul Moriarty; Donal O'Shea
Journal:  BMJ       Date:  2004-08-14

Review 4.  [Endocrine orbit disorders. Pathogenesis, clinical presentation and examination, stage-dependent therapy].

Authors:  A Eckstein; J Esser
Journal:  Ophthalmologe       Date:  2003-10       Impact factor: 1.059

5.  Efficacy of combined orbital radiation and systemic steroids in the management of Graves' orbitopathy.

Authors:  Ji Won Kim; Sun Hyup Han; Byeong Jae Son; Tyler Hyungtaek Rim; Ki Chang Keum; Jin Sook Yoon
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-02-15       Impact factor: 3.117

Review 6.  Pharmacological treatments for thyroid eye disease.

Authors:  Sara P Modjtahedi; Bobeck S Modjtahedi; Ahmad M Mansury; Dinesh Selva; Raymond S Douglas; Robert A Goldberg; Igal Leibovitch
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 7.  Graves orbitopathy: a perspective.

Authors:  Petros Perros; Gerasimos E Krassas
Journal:  Nat Rev Endocrinol       Date:  2009-06       Impact factor: 43.330

8.  Effect of radiotherapy on moderate and severe thyroid associated ophthalmopathy: a double blind and self-controlled study.

Authors:  Yujie Wu; Boding Tong; Yongheng Luo; Guiyuan Xie; Wei Xiong
Journal:  Int J Clin Exp Med       Date:  2015-02-15

9.  [Drug therapy and radiotherapy in Graves' orbitopathy].

Authors:  F Beisse; W A Lagrèze; M Schmucker
Journal:  Ophthalmologe       Date:  2011-05       Impact factor: 1.059

10.  Update on thyroid eye disease and management.

Authors:  Erick D Bothun; Ryan A Scheurer; Andrew R Harrison; Michael S Lee
Journal:  Clin Ophthalmol       Date:  2009-10-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.